Vimal Mehta | executive |
Richard Steinhart | executive |
Greg Harrison | analyst |
Robert Risinger | executive |
Raghuram Selvaraju | analyst |
Matthew Wiley | executive |
Vincent O'Neill | executive |
Sumant Kulkarni | analyst |
Colin Bristow | analyst |
Robyn Karnauskas | analyst |
Graig Suvannavejh | analyst |
Corinne Jenkins | analyst |
Good morning, and welcome to the BioXcel Therapeutics Conference Call, which will cover its alignment with the FDA on its TRANQUILITY program, provide an update on strategic financing, and review its financial results for the Third Quarter of 2023. At this time, all participants are in a listen-only mode. [Operator Instructions] After the presentation, there will be a question-and-answer session. [Operator Instructions]Just to remind everyone, certain matters discussed in today's conference call and or answers that may be given to questions asked are forward-looking statements that are subject to risks and uncertainties related to future events and/or the future financial or business performance of the company. Actual results could differ materially from those anticipated in these forward-looking statements.